<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31818821</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e02372-19</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.02372-19</ELocationID><Abstract><AbstractText>Viruses in species <i>Parechovirus A</i> (<i>Picornaviridae</i>) are associated with a wide variety of clinical manifestations. Parechovirus A3 (PeV-A3) is known to cause sepsis-like illness, meningitis, and encephalitis in infants and young children. To date, no specific therapies are available to treat PeV-A3-infected children. We had previously identified two FDA-cleared antifungal drugs, itraconazole (ITC) and posaconazole (POS), with potent and specific antiviral activity against PeV-A3. Time-of-addition and synchronized infection assays revealed that POS targets an early stage of the PeV-A3 life cycle. POS exerts an antiviral effect, evidenced by a reduction in viral titer following the addition of POS to Vero-P cells before infection, coaddition of POS and PeV-A3 to Vero-P cells, incubation of POS and PeV-A3 prior to Vero-P infection, and at attachment. POS exerts less of an effect on virus entry. A PeV-A3 enzyme-linked immunosorbent assay inhibition experiment, using an anti-PeV-A3 monoclonal antibody, suggested that POS binds directly to the PeV-A3 capsid. POS-resistant PeV-A3 strains developed by serial passage in the presence of POS acquired substitutions in multiple regions of the genome, including the capsid. Reverse genetics confirmed substitutions in capsid proteins VP0, VP3, and VP1 and nonstructural proteins 2A and 3A. Single mutants VP0_K66R, VP0_A124T, VP3_N88S, VP1_Y224C, 2A_S78L, and 3A_T1I were 4-, 9-, 12-, 34-, 51-, and 119-fold more resistant to POS, respectively, than the susceptible prototype strain. Our studies demonstrate that POS may be a valuable tool in developing an antiviral therapy for PeV-A3.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rhoden</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA erhoden@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Terry Fei Fan</ForeName><Initials>TFF</Initials><Identifier Source="ORCID">0000-0002-4815-8697</Identifier><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campagnoli</LastName><ForeName>Ray</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nix</LastName><ForeName>W Allan</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konopka-Anstadt</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvarangan</LastName><ForeName>Rangaraj</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Children's Mercy Hospital, Kansas City, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briesach</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IHRC, Inc., Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberste</LastName><ForeName>M Steven</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weldon</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014230">Triazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>304NUG5GF4</RegistryNumber><NameOfSubstance UI="D017964">Itraconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>6TK1G07BHZ</RegistryNumber><NameOfSubstance UI="C101425">posaconazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017964" MajorTopicYN="N">Itraconazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030061" MajorTopicYN="N">Parechovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">itraconazole</Keyword><Keyword MajorTopicYN="N">parechovirus</Keyword><Keyword MajorTopicYN="N">posaconazole</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31818821</ArticleId><ArticleId IdType="pmc">PMC7038243</ArticleId><ArticleId IdType="doi">10.1128/AAC.02372-19</ArticleId><ArticleId IdType="pii">AAC.02372-19</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams MJ, Lefkowitz EJ, King AMQ, Harrach B, Harrison RL, Knowles NJ, Kropinski AM, Krupovic M, Kuhn JH, Mushegian AR, Nibert M, Sabanadzovic S, Sanfacon H, Siddell SG, Simmonds P, Varsani A, Zerbini FM, Gorbalenya AE, Davison AJ. 2017. Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2017). Arch Virol 162:2505&#x2013;2538. doi:10.1007/s00705-017-3358-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-017-3358-5</ArticleId><ArticleId IdType="pubmed">28434098</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyypia T, Horsnell C, Maaronen M, Khan M, Kalkkinen N, Auvinen P, Kinnunen L, Stanway G. 1992. A distinct picornavirus group identified by sequence analysis. Proc Natl Acad Sci U S A 89:8847&#x2013;8851. doi:10.1073/pnas.89.18.8847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.18.8847</ArticleId><ArticleId IdType="pmc">PMC50018</ArticleId><ArticleId IdType="pubmed">1528901</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapparel C, Siegrist F, Petty TJ, Kaiser L. 2013. Picornavirus and enterovirus diversity with associated human diseases. Infect Genet Evol 14:282&#x2013;293. doi:10.1016/j.meegid.2012.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2012.10.016</ArticleId><ArticleId IdType="pubmed">23201849</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvala H, Simmonds P. 2009. Human parechoviruses: biology, epidemiology and clinical significance. J Clin Virol 45:1&#x2013;9. doi:10.1016/j.jcv.2009.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.03.009</ArticleId><ArticleId IdType="pubmed">19372062</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanway G, Hyypia T. 1999. Parechoviruses. J Virol 73:5249&#x2013;5254. doi:10.1128/JVI.73.7.5249-5254.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.7.5249-5254.1999</ArticleId><ArticleId IdType="pmc">PMC112579</ArticleId><ArticleId IdType="pubmed">10364270</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvala H, Wolthers KC, Simmonds P. 2010. Parechoviruses in children: understanding a new infection. Curr Opin Infect Dis 23:224&#x2013;230. doi:10.1097/qco.0b013e32833890ca.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/qco.0b013e32833890ca</ArticleId><ArticleId IdType="pubmed">20414971</ArticleId></ArticleIdList></Reference><Reference><Citation>Merilahti P, Koskinen S, Heikkila O, Karelehto E, Susi P. 2012. Endocytosis of integrin-binding human picornaviruses. Adv Virol 2012:547530. doi:10.1155/2012/547530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/547530</ArticleId><ArticleId IdType="pmc">PMC3514805</ArticleId><ArticleId IdType="pubmed">23227048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bissel SJ, Auer RN, Chiang CH, Kofler J, Murdoch GH, Nix WA, Painter M, Richer M, Sartelet H, Wang G, Wiley CA. 2015. Human parechovirus 3 meningitis and fatal leukoencephalopathy. J Neuropathol Exp Neurol 74:767&#x2013;777. doi:10.1097/NEN.0000000000000215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0000000000000215</ArticleId><ArticleId IdType="pubmed">26115191</ArticleId></ArticleIdList></Reference><Reference><Citation>Felsenstein S, Yang S, Eubanks N, Sobrera E, Grimm JP, Aldrovandi G. 2014. Human parechovirus central nervous system infections in southern California children. Pediatr Infect Dis J 33:e87&#x2013;e91. doi:10.1097/INF.0000000000000112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000112</ArticleId><ArticleId IdType="pubmed">24104958</ArticleId></ArticleIdList></Reference><Reference><Citation>Levorson RE, Jantausch BA, Wiedermann BL, Spiegel HM, Campos JM. 2009. Human parechovirus-3 infection: emerging pathogen in neonatal sepsis. Pediatr Infect Dis J 28:545&#x2013;547. doi:10.1097/INF.0b013e318194596a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e318194596a</ArticleId><ArticleId IdType="pubmed">19483524</ArticleId></ArticleIdList></Reference><Reference><Citation>Verboon-Maciolek MA, Groenendaal F, Hahn CD, Hellmann J, van Loon AM, Boivin G, de Vries LS. 2008. Human parechovirus causes encephalitis with white matter injury in neonates. Ann Neurol 64:266&#x2013;273. doi:10.1002/ana.21445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21445</ArticleId><ArticleId IdType="pubmed">18825694</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolthers KC, Benschop KS, Schinkel J, Molenkamp R, Bergevoet RM, Spijkerman IJ, Kraakman HC, Pajkrt D. 2008. Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children. Clin Infect Dis 47:358&#x2013;363. doi:10.1086/589752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/589752</ArticleId><ArticleId IdType="pubmed">18558876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q, Yuan S, Zhang C, Wang Y, Wang Y, He G, Zhang S, Altmeyer R, Zou G. 2015. Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob Agents Chemother 59:2654&#x2013;2665. doi:10.1128/AAC.05108-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05108-14</ArticleId><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>Strating JR, van der Linden L, Albulescu L, Bigay J, Arita M, Delang L, Leyssen P, van der Schaar HM, Lanke KH, Thibaut HJ, Ulferts R, Drin G, Schlinck N, Wubbolts RW, Sever N, Head SA, Liu JO, Beachy PA, De Matteis MA, Shair MD, Olkkonen VM, Neyts J, van Kuppeveld FJ. 2015. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep 10:600&#x2013;615. doi:10.1016/j.celrep.2014.12.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.12.054</ArticleId><ArticleId IdType="pmc">PMC4383725</ArticleId><ArticleId IdType="pubmed">25640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Choi HJ, Song JH, Ko HJ, Yoon K, Seong JM. 2017. Antiviral activity of itraconazole against echovirus 30 infection in vitro. Osong Public Health Res Perspect 8:318&#x2013;324. doi:10.24171/j.phrp.2017.8.5.05.</Citation><ArticleIdList><ArticleId IdType="doi">10.24171/j.phrp.2017.8.5.05</ArticleId><ArticleId IdType="pmc">PMC5678193</ArticleId><ArticleId IdType="pubmed">29164043</ArticleId></ArticleIdList></Reference><Reference><Citation>Meutiawati F, Bezemer B, Strating J, Overheul GJ, Zusinaite E, van Kuppeveld FJM, van Cleef KWR, van Rij RP. 2018. Posaconazole inhibits dengue virus replication by targeting oxysterol-binding protein. Antiviral Res 157:68&#x2013;79. doi:10.1016/j.antiviral.2018.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.06.017</ArticleId><ArticleId IdType="pubmed">29981375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoden E, Nix WA, Weldon WC, Selvarangan R. 2018. Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae). Antiviral Res 149:75&#x2013;77. doi:10.1016/j.antiviral.2017.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.11.011</ArticleId><ArticleId IdType="pmc">PMC9169550</ArticleId><ArticleId IdType="pubmed">29155163</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Liu CH, Wang GH, Jassey A, Li CL, Chen L, Yen MH, Lin CC, Lin LT. 2016. (4R,6S)-2-dihydromenisdaurilide is a butenolide that efficiently inhibits hepatitis C virus entry. Sci Rep 6:29969. doi:10.1038/srep29969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep29969</ArticleId><ArticleId IdType="pmc">PMC4947960</ArticleId><ArticleId IdType="pubmed">27426693</ArticleId></ArticleIdList></Reference><Reference><Citation>Prichard MN, Shipman C Jr.. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14:181&#x2013;205. doi:10.1016/0166-3542(90)90001-N.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(90)90001-N</ArticleId><ArticleId IdType="pubmed">2088205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo VA, Cross SJ, Crews KR, Flynn PM, Hoffman JM, Knapp KM, Pauley JL, Molinelli AR, Greene WL. 2013. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother 47:976&#x2013;983. doi:10.1345/aph.1R775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1345/aph.1R775</ArticleId><ArticleId IdType="pmc">PMC4384822</ArticleId><ArticleId IdType="pubmed">23737511</ArticleId></ArticleIdList></Reference><Reference><Citation>Doring M, Cabanillas Stanchi KM, Klinker H, Eikemeier M, Feucht J, Blaeschke F, Schwarze CP, Ebinger M, Feuchtinger T, Handgretinger R, Heinz WJ. 2017. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. Med Mycol 55:375&#x2013;384. doi:10.1093/mmy/myw091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/mmy/myw091</ArticleId><ArticleId IdType="pubmed">27703016</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. 2007. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 51:812&#x2013;818. doi:10.1128/AAC.00454-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00454-06</ArticleId><ArticleId IdType="pmc">PMC1803109</ArticleId><ArticleId IdType="pubmed">17210771</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz WJ, Cabanillas Stanchi KM, Klinker H, Blume O, Feucht J, Hartmann U, Feuchtinger T, Lang P, Handgretinger R, D&#xf6;ring M. 2016. Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. Med Mycol 54:128&#x2013;137. doi:10.1093/mmy/myv087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/mmy/myv087</ArticleId><ArticleId IdType="pubmed">26483433</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicenzi EB, Calore E, Decembrino N, Berger M, Perruccio K, Carraro F, Rossin S, Putti MC, Molinaro M, Tridello G, Cesaro S. 2018. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients. Eur J Haematol 100:315&#x2013;322. doi:10.1111/ejh.13017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13017</ArticleId><ArticleId IdType="pubmed">29240266</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickless JR, Bridger KE, Vora SB, Brothers AW. 2018. Evaluation of intravenous posaconazole dosing and pharmacokinetic target attainment in pediatric patients. J Pediatric Infect Dis Soc 8:365&#x2013;367. doi:10.1093/jpids/piy094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piy094</ArticleId><ArticleId IdType="pubmed">30299489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L, Ferla S, Head SA, Bhat S, Pasunooti KK, Shi WQ, Albulescu L, Liu JO, Brancale A, van Kuppeveld FJM, Strating J. 2018. Structure-activity relationship study of itraconazole, a broad-range inhibitor of picornavirus replication that targets oxysterol-binding protein (OSBP). Antiviral Res 156:55&#x2013;63. doi:10.1016/j.antiviral.2018.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.05.010</ArticleId><ArticleId IdType="pubmed">29807040</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski CA. 2004. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1:337&#x2013;341. doi:10.1016/j.ddtec.2004.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ddtec.2004.11.007</ArticleId><ArticleId IdType="pubmed">24981612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanko K, Ma Y, Delang L, Mirabelli C, Neyts J. 2019. Antiviral effects of selected nucleoside analogues against human parechoviruses A1 and A3. Antiviral Res 162:51&#x2013;53. doi:10.1016/j.antiviral.2018.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.12.009</ArticleId><ArticleId IdType="pubmed">30550798</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay MA, Pevear DC, Rossmann MG. 1992. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu Rev Microbiol 46:635&#x2013;654. doi:10.1146/annurev.mi.46.100192.003223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.46.100192.003223</ArticleId><ArticleId IdType="pubmed">1332585</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Vliegen I, De Clercq E, Neyts J. 2008. Selective inhibitors of picornavirus replication. Med Res Rev 28:823&#x2013;884. doi:10.1002/med.20125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.20125</ArticleId><ArticleId IdType="pubmed">18381747</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaut HJ, De Palma AM, Neyts J. 2012. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol 83:185&#x2013;192. doi:10.1016/j.bcp.2011.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2011.08.016</ArticleId><ArticleId IdType="pubmed">21889497</ArticleId></ArticleIdList></Reference><Reference><Citation>Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, Sanchez PJ, Wilson G, Krogstad P, Storch GA, Lawrence R, Shelton M, Palmer A, Robinson J, Dennehy P, Sood SK, Cloud G, Jester P, Acosta EP, Whitley R, Kimberlin D, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group . 2016. A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis. J Pediatric Infect Dis Soc 5:53&#x2013;62. doi:10.1093/jpids/piv015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piv015</ArticleId><ArticleId IdType="pmc">PMC4765488</ArticleId><ArticleId IdType="pubmed">26407253</ArticleId></ArticleIdList></Reference><Reference><Citation>Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, Liu H, Oberste MS, McKinlay MA, Hartford M. 2017. Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model. J Infect Dis 215:335&#x2013;343. doi:10.1093/infdis/jiw542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw542</ArticleId><ArticleId IdType="pmc">PMC5393058</ArticleId><ArticleId IdType="pubmed">27932608</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Torres S, Myers AL, Klatte JM, Rhoden EE, Oberste MS, Collett MS, McCulloh RJ. 2015. First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis. Pediatr Infect Dis J 34:52&#x2013;54. doi:10.1097/INF.0000000000000497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000497</ArticleId><ArticleId IdType="pubmed">25229269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittekind SG, Allen CC, Jefferies JL, Rattan MS, Madueme PC, Taylor BN, Moore RA. 2017. Neonatal enterovirus myocarditis with severe dystrophic calcification: novel treatment with pocapavir. J Investig Med High Impact Case Rep 5:2324709617729393. doi:10.1177/2324709617729393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2324709617729393</ArticleId><ArticleId IdType="pmc">PMC5602221</ArticleId><ArticleId IdType="pubmed">28944227</ArticleId></ArticleIdList></Reference><Reference><Citation>Amdani SM, Kim HS, Orvedahl A, John AO, Said A, Simpson K. 2018. Successful treatment of fulminant neonatal enteroviral myocarditis in monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir. BMJ Case Rep 2018:bcr-2017-224133. doi:10.1136/bcr-2017-224133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2017-224133</ArticleId><ArticleId IdType="pmc">PMC5965763</ArticleId><ArticleId IdType="pubmed">29776940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Abdelnabi R, Delang L, Froeyen M, Luyten W, Neyts J, Mirabelli C. 2017. New class of early-stage enterovirus inhibitors with a novel mechanism of action. Antiviral Res 147:67&#x2013;74. doi:10.1016/j.antiviral.2017.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.10.004</ArticleId><ArticleId IdType="pubmed">28993161</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, Hare RS, Hardalo CJ. 2005. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56:745&#x2013;755. doi:10.1093/jac/dki288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dki288</ArticleId><ArticleId IdType="pubmed">16135526</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinwald M, Uharek L, Lampe D, Grobosch T, Thiel E, Schwartz S. 2009. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis. Bone Marrow Transplant 44:269&#x2013;270. doi:10.1038/bmt.2009.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2009.17</ArticleId><ArticleId IdType="pubmed">19219077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruping MJ, Albermann N, Ebinger F, Burckhardt I, Beisel C, Muller C, Vehreschild JJ, Kochanek M, Fatkenheuer G, Bangard C, Ullmann AJ, Herr W, Kolbe K, Hallek M, Cornely OA. 2008. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother 62:1468&#x2013;1470. doi:10.1093/jac/dkn409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkn409</ArticleId><ArticleId IdType="pubmed">18824458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiederhold NP, Pennick GJ, Dorsey SA, Furmaga W, Lewis JS II, Patterson TF, Sutton DA, Fothergill AW. 2014. A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother 58:424&#x2013;431. doi:10.1128/AAC.01558-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01558-13</ArticleId><ArticleId IdType="pmc">PMC3910734</ArticleId><ArticleId IdType="pubmed">24189246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedmak G, Nix WA, Jentzen J, Haupt TE, Davis JP, Bhattacharyya S, Pallansch MA, Oberste MS. 2010. Infant deaths associated with human parechovirus infection in Wisconsin. Clin Infect Dis 50:357&#x2013;361. doi:10.1086/649863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/649863</ArticleId><ArticleId IdType="pubmed">20047496</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xe4;rber G. 1931. 50% End point calculation. Arch Exp Pathol Pharmakol 162:48&#x2013;483.</Citation></Reference><Reference><Citation>Rhoden E, Liu HM, Wang-Chern SW, Oberste MS. 2013. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antiviral Res 98:186&#x2013;191. doi:10.1016/j.antiviral.2013.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.03.003</ArticleId><ArticleId IdType="pubmed">23499651</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. 2004. Polio laboratory manual, 4th ed World Health Organization, Geneva, Switzerland.</Citation></Reference><Reference><Citation>Montmayeur AM, Ng TF, Schmidt A, Zhao K, Magana L, Iber J, Castro CJ, Chen Q, Henderson E, Ramos E, Shaw J, Tatusov RL, Dybdahl-Sissoko N, Endegue-Zanga MC, Adeniji JA, Oberste MS, Burns CC. 2017. High-throughput next-generation sequencing of polioviruses. J Clin Microbiol 55:606&#x2013;615. doi:10.1128/JCM.02121-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02121-16</ArticleId><ArticleId IdType="pmc">PMC5277531</ArticleId><ArticleId IdType="pubmed">27927929</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772&#x2013;780. doi:10.1093/molbev/mst010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/mst010</ArticleId><ArticleId IdType="pmc">PMC3603318</ArticleId><ArticleId IdType="pubmed">23329690</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sheng J, Fokine A, Meng G, Shin WH, Long F, Kuhn RJ, Kihara D, Rossmann MG. 2015. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science 347:71&#x2013;74. doi:10.1126/science.1261962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1261962</ArticleId><ArticleId IdType="pmc">PMC4307789</ArticleId><ArticleId IdType="pubmed">25554786</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>